We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Plan to Reassess Approved Pediatric Drugs Prompts Industry Pushback
EMA Plan to Reassess Approved Pediatric Drugs Prompts Industry Pushback
January 10, 2013
A European Medicines Agency draft guideline on pediatric drug development that requires regular reevaluations of approved drug products has prompted pushback from drugmakers, which see it as costly and retrospective.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor